https://www.hcp.novartis.com/products/pluvicto/psma-positive-mcrpc/efficacy/
46% OF PATIENTS WHO RECEIVED PLUVICTO + BSOC HAD A PSA DECLINE ≥50% VS 7% OF PATIENTS WHO RECEIVED BSOC ALONE3
versus TLX "64% of patients (baseline PSA and full dose) had a PSA reduction, with 27% demonstrating a 30% reduction and 18% demonstrating a 50% reduction. PSA and rPFS monitoring is ongoing"
Ann: Q3 2023 Business Update to Accompany Quarterly Results, page-59
-
- There are more pages in this discussion • 80 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.48 |
Change
-0.240(1.35%) |
Mkt cap ! $5.849B | |||
| Open | High | Low | Value | Volume |
| $17.62 | $17.68 | $17.48 | $16.91M | 963.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5669 | $17.48 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.57 | 3102 | 2 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| TLX (ASX) Chart |